An investigational drug treatment for patients who have been hospitalized with the coronavirus COVID-19; University Campus
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
What we're hoping for
We are hoping that the experimental drug is safe for use and helps people hospitalized with the COVID-19 coronavirus recover.
ClinicalTrials.gov Identifier: NCT04323761